Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2020 | Efficacy of haploidentical SCT for R/R classical Hodgkin lymphoma

Ivan Moiseev • 1 Sep 2020
EBMT 2020
Hodgkin Lymphoma Lymphoma

Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, discusses the efficacy of haploidentical stem cell transplantation (SCT) in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma, in comparison to matched-related donors. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ivan Moiseev

Significance of MRD negativity in Ph-negative ALL 1:01
Significance of MRD negativity in Ph-negative ALL
Ivan Moiseev • 1 Sep 2020
GO-FLAG: bridge therapy to allo-SCT in R/R AML 0:53
GO-FLAG: bridge therapy to allo-SCT in R/R AML
Ivan Moiseev • 30 Aug 2020
Impact of post-transplant TKIs on long-term outcomes of allo-HSCT in ALL 1:27
Impact of post-transplant TKIs on long-term outcomes of allo-HSCT in ALL
Ivan Moiseev • 1 Sep 2020
Mutational profiles of MDS patients undergoing allo-HSCT 1:29
Mutational profiles of MDS patients undergoing allo-HSCT
Ivan Moiseev • 30 Aug 2020

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals